145 related articles for article (PubMed ID: 9759617)
1. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates.
Köhler M; Hellstern P; Lechler E; Uberfuhr P; Müller-Berghaus G
Thromb Haemost; 1998 Sep; 80(3):399-402. PubMed ID: 9759617
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis risk in cardiac surgery patients receiving factor IX concentrates.
Rossiter SJ; Miller DC; Raney AA; Oyer PE; Reitz BA; Stinson EB; Shumway NE
J Thorac Cardiovasc Surg; 1979 Aug; 78(2):203-7. PubMed ID: 459527
[TBL] [Abstract][Full Text] [Related]
3. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo.
Hedner U; Nilsson IM; Bergentz SE
Thromb Haemost; 1976 Apr; 35(2):386-95. PubMed ID: 989639
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
[TBL] [Abstract][Full Text] [Related]
5. [Substitution therapy with prothrombin complex concentrates in acquired coagulation disorders].
Fischer M
Wien Klin Wochenschr; 1983 Feb; 95(3):82-5. PubMed ID: 6858171
[TBL] [Abstract][Full Text] [Related]
6. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
7. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
McLaughlin LF; Drummond O; MacGregor IR
Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
[TBL] [Abstract][Full Text] [Related]
8. Thrombogenicity of prothrombin complex concentrates.
Köhler M
Thromb Res; 1999 Aug; 95(4 Suppl 1):S13-7. PubMed ID: 10499904
[TBL] [Abstract][Full Text] [Related]
9. Low doses of aprotinin in aortocoronary bypass surgery--advantages and disadvantages.
Golański R; Golański J; Chizyński K; Iwaszkiewicz A; Zasłonka J; Pietrucha T; Chrul S; Watała C
Med Sci Monit; 2000; 6(4):722-8. PubMed ID: 11208399
[TBL] [Abstract][Full Text] [Related]
10. [Use and abuse of prothrombin-complex concentrates].
Veltkamp JJ; Siewertz van Reesema DR; Boekhout-Mussert MJ
Ned Tijdschr Geneeskd; 1978 May; 122(21):766-7. PubMed ID: 652091
[No Abstract] [Full Text] [Related]
11. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
13. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate.
Pabinger-Fasching I
Thromb Res; 2008; 122 Suppl 2():S19-22. PubMed ID: 18549908
[TBL] [Abstract][Full Text] [Related]
14. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
[TBL] [Abstract][Full Text] [Related]
15. [Clinical use of factor IX concentrates].
Nyman D
Schweiz Med Wochenschr; 1975 Sep; 105(37):1188-90. PubMed ID: 1215901
[TBL] [Abstract][Full Text] [Related]
16. Prothrombin complex concentrate (Beriplex P/N)-related renal and cerebral infarctions in a patient with warfarin-associated intracerebral hemorrhage.
Lin SY; Tang SC; Shen LJ; Jeng JS
J Stroke Cerebrovasc Dis; 2015 Jan; 24(1):e15-6. PubMed ID: 25282184
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and in vivo properties of high purity factor IX concentrates.
Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
Levi M; Toh CH; Thachil J; Watson HG
Br J Haematol; 2009 Apr; 145(1):24-33. PubMed ID: 19222477
[TBL] [Abstract][Full Text] [Related]
19. Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate.
Warren O; Simon B
Ann Emerg Med; 2009 Jun; 53(6):758-61. PubMed ID: 19181420
[TBL] [Abstract][Full Text] [Related]
20. Current management of hemophilia B.
Roberts HR; Eberst ME
Hematol Oncol Clin North Am; 1993 Dec; 7(6):1269-80. PubMed ID: 8294316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
